Emerging therapies for inv (16) AML
S Surapally, DG Tenen… - Blood, The Journal of the …, 2021 - ashpublications.org
The core binding factor composed of CBFβ and RUNX subunits plays a critical role in most
hematopoietic lineages and is deregulated in acute myeloid leukemia (AML). The fusion …
hematopoietic lineages and is deregulated in acute myeloid leukemia (AML). The fusion …
[HTML][HTML] Targeting miR-126 in inv (16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance
L Zhang, LXT Nguyen, YC Chen, D Wu… - Nature …, 2021 - nature.com
Acute myeloid leukemia (AML) harboring inv (16)(p13q22) expresses high levels of miR-
126. Here we show that the CBFB-MYH11 (CM) fusion gene upregulates miR-126 …
126. Here we show that the CBFB-MYH11 (CM) fusion gene upregulates miR-126 …
[HTML][HTML] How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual …
A Talami, F Bettelli, V Pioli, D Giusti, A Gilioli… - Biomedicines, 2021 - mdpi.com
Acute myeloid leukemia (AML) carrying inv (16)/t (16; 16), resulting in fusion transcript CBFB-
MYH11, belongs to the favorable-risk category. However, even if most patients obtain …
MYH11, belongs to the favorable-risk category. However, even if most patients obtain …
[HTML][HTML] Comprehensive analysis for cellular senescence-related immunogenic characteristics and immunotherapy prediction of acute myeloid leukemia
Y Mao, J Xu, X Xu, J Qiu, Z Hu, F Jiang… - Frontiers in …, 2022 - frontiersin.org
In malignancies, cellular senescence is critical for carcinogenesis, development, and
immunological regulation. Patients with acute myeloid leukemia (AML) have not investigated …
immunological regulation. Patients with acute myeloid leukemia (AML) have not investigated …
[HTML][HTML] Outcome and prognostic factors of CBF pediatric AML patients with t (8; 21) differ from patients with inv (16)
K Qiu, X Liao, Y Li, K Huang, H Xu, J Fang, D Zhou - BMC cancer, 2023 - Springer
Purpose To explore the outcome and prognostic factors between inv (16) and t (8; 21)
disrupt core binding factor (CBF) in acute myeloid leukemia (AML). Methods The clinical …
disrupt core binding factor (CBF) in acute myeloid leukemia (AML). Methods The clinical …
[HTML][HTML] BAALC-экспрессирующие лейкозные гемопоэтические стволовые клетки и их место в изучении CBF-позитивных острых миелоидных лейкозов у …
ММ Канунников, НН Мамаев, ТЛ Гиндина… - Клиническая …, 2023 - cyberleninka.ru
Актуальность. В связи с изменением представлений о патогенезе, факторах риска и
принципах терапии прогностически благоприятных CBF-позитивных острых …
принципах терапии прогностически благоприятных CBF-позитивных острых …